Markets
markets
Luke Kawa

Flurry of positive announcements make ImmunityBio the next short squeeze target for retail traders

Heavily shorted ImmnuityBio is continuing its stellar run, up big in premarket trading after management delivered its fourth and fifth doses of positive news for the week.

In a pair of press releases, the biotech company said that:

  • A trial aiming to advance the utilization of its bladder cancer drug (ANKTIVA) is over 85% complete, with interim analysis having been positive.

  • A study of one of its treatments delivered in concert with another drug helped patients stay clear of Waldenstrom Non-Hodgkins Lymphoma for up to 15 months.

At their premarket peak on Friday, shares had more than doubled on the week.

The stock jumped 30% on Thursday after management said that ANKTIVA volume sales rose 750% in 2025. That came on the heels of a 7% rise on Wednesday after Saudi Arabia approved this drug as part of a treatment for bladder cancer and non-small cell lung cancer. And that followed a release from the company on Tuesday about how ANKTIVA “demonstrated statistically significant immune restoration across two clinical trials in 151 patients with non-small cell lung cancer,” driving shares up nearly 9%.

About 36.5% of the company’s shares were sold short as of the start of this year, and retail traders are clearly of the view that those betting against the company will be forced to capitulate amid this litany of positive releases. As of 7:30 a.m. ET, two of the top three posts on the r/ShortSqueeze subreddit center on the biotech firm, with one of these a cross-post from r/WallStreetBets of a more than $90,000 position initiated after the close on Thursday.

This may be another instance in which the term “short squeeze” looks like a bit of a misnomer: as of year-end 2025, about 120.6 million shares of IBRX were sold short, per exchange data. Cumulative volumes over the past three full sessions have been above 150 million. So going forward, if there are shorts left to be squeezed, it’s because this three-day spike (going on four days!) had much more to do with a buyer’s binge thanks to this string of encouraging news.

More Markets

See all Markets
markets
Max Knoblauch

United beats Q1 earnings and revenue estimates, lowers full-year profit guidance amid surging jet fuel prices

United Airlines reported its first-quarter earnings results after the bell on Tuesday. The carrier’s shares ticked down in after hours trading.

For Q1, United reported:

  • Adjusted earnings of $1.19 per share, compared to the Wall Street estimate of $1.08 per share compiled by FactSet.

  • $14.6 billion in revenue, compared to the $14.39 billion estimates.

In the first quarter, United’s fuel expense grew 12.6% from the same period last year to $3.04 billion.

For the second quarter, United expects adjusted earnings per share of between $1 and $2, shy of Wall Street expectations of $2.08. For the full year ahead, United said it expects earnings between $7 and $11 per share, compared to its prior guidance of between $12 and $14 per share.

“Guidance assumes United’s revenue recovers 40% to 50% of the fuel price increases in the second quarter, 70% to 80% of the fuel price increases in the third quarter and 85% to 100% of the fuel price increases in the fourth quarter 2026,” read the company’s investor update.

Earlier this month, United was among the first major US airlines to hike its bag fees amid higher fuel costs. Its shares have fallen more than 15% from a February high days before the war in Iran began.

United has also made waves this month following reports that CEO Scott Kirby had floated the idea of a merger with American Airlines to President Trump. A merger between two of the big four airlines would create a true US behemoth, controlling more than a third of the American market. American Air last week said it wasn’t interested in merging with United and hadn’t held talks on the idea. On Tuesday, President Trump told CNBC that he doesn’t like the idea either.

Tasha Matsumoto
31m
Stocks slip as peace prospects dim

Stocks swung from positive to negative as Vice President Vance's trip to Pakistan for Iran peace talks was canceled.

Grizzly bear growling USA.
markets
Luke Kawa

Hedge funds are following retail traders into the Magnificent 7

Hedge funds are following retail traders into the stocks the masses never stopped buying.

“As we kick off earnings for megacap tech stocks, this stood out: [hedge funds] have started buying Mag7 stocks again this month though positioning remains well below the peak levels seen in early 2016,” writes Goldman Sachs’ Cullen Morgan.

Goldman PB Mag 7
Source: Goldman Sachs

In early April, JPMorgan strategist Arun Jain noted that retail investors had basically been selling everything but the Magnificent 7 stocks as part of a more cautious stance due to the Iran war.

(Apple has been a longstanding exception to this trend, presumably because retail traders aren't fond of its hands-off approach to AI.)

JPM Retail flows

Last August, Jain discussed how retail activity tended to “crowd in” institutional buyers in meme stocks, while Goldman’s John Marshall advised clients to piggyback on stocks beloved by retail traders. Speculative, retail-geared assets proceeded to go on a tremendous run that soured in October.

But there are some early indications that a similar bout of speculative fervor is bubbling up once more.

markets
Luke Kawa

POET Technologies surges above $10 for first time in 4 years amid explosion in call volumes

POET Technologies is up nearly 40% this week as options market activity goes haywire in a faint echo of what got the stock on retail traders’ radars in October.

As of 11:12 a.m. ET, more than 10 calls have changed hands for every put traded. This bullish impulse has propelled the stock above the $10 threshold for the first time since March 2022.

Shares of the optical communications firm briefly dipped last week after Wolfpack Research said it was short the company because its investors would be exposed to an “IRS tax nightmare.”

The company responded that day saying it was taking measures for US shareholders that “should mitigate certain potential adverse US federal income tax consequences to it that could otherwise result from the Company’s status as a passive foreign investment company.”

Luke Kawa
6h
The parabolic surge in Avis reached new heights, with shares halted for volatility

More motivated buyers than motivated sellers.

Travelers at Sacramento International Airport (SMF)

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.
©2026 Sherwood Media, LLC